Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.

Trial Details

NCT ID
NCT06810544
Phase
PHASE1 / PHASE2
Sponsor
Tango Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • TNG456
  • abemaciclib
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Irvine, California, United States|33.66946,-117.82311
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Francisco, California, United States|37.77493,-122.41942
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637

Key Eligibility Criteria

  • Has a tumor with a confirmed MTAP loss
  • Is ≥18 years of age at the time of signature of the main study ICF
  • Has had progression or an inadequate response to or is intolerant of the approved standard of care therapy, no standard of care therapy exists, or …
  • Is able to swallow tablets

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →